Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Salarius Pharmaceuticals, Inc. (FLKS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/12/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/01/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 05/26/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/25/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 05/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/05/2023 |
4
| Lieber Jonathan I (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| McCreedy Bruce J Jr. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| HANISH ARNOLD C (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| Lammers Paul (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| Burleson Tess (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| McVicar William K. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| Rosenblum Mark J (Exec VP Finance, CFO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 8,000 shares
@ $0 |
|
| 01/05/2023 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 shares
@ $0 |
|
| 12/12/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 12/12/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 12/01/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 11/08/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 11/07/2022 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 shares
@ $1.734, valued at
$17.3k
|
|
| 11/07/2022 |
4
| Rosenblum Mark J (Exec VP Finance, CFO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 7,314 shares
@ $1.734, valued at
$12.7k
|
|
| 11/03/2022 |
8-K
| Quarterly results |
|
|
|